Riociguat in Children With Pulmonary Arterial Hypertension (PAH)
Phase 3
Active, not recruiting
NCT02562235
| Condition | Hypertension, Pulmonary |
|---|
| Phase | Phase 3 |
|---|
| Sponsor | Bayer |
|---|
| Status | Active, not recruiting |
|---|
| Enrollment | 24 participants |
|---|
| Interventions | Riociguat (Adempas, BAY63-2521) |
|---|
| Start date | Oct 29, 2015 |
|---|
| Completion date | Mar 7, 2020 |
|---|
| Results posted | May 17, 2021 |
|---|
Summary
This study was designed to evaluate the safety, tolerability, pharmacodynamics and pharmacokinetics of riociguat at age-, sex- and body-weight-adjusted doses of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID in children from ≥6 to less than 18 years with pulmonary arterial hypertension (PAH) group 1. The study design consisted of a main study part followed by an optional long-term extension part. The main treatment period consisted of two phases: titration phase up to 8 weeks and a maintenance phase up to 16 weeks.
Number of Participants With Any Treatment-emergent Adverse Events
From start of study drug up to 2 days after the last dose of study drug in the main study part, up to 24 weeks plus/minus 5 days. · Participants
| Riociguat >=6 to <18 Years | 20 Participants |
|---|
| Riociguat >=6 to <18 Years | 4 Participants |
|---|
Change in Heart Rate From Baseline
Baseline and Week 24 (plus/minus 5 days) · Beats per minute (BPM)
| Riociguat >=6 to <18 Years | 4.1 ± 10.1 Beats per minute (BPM) |
|---|
Change in Blood Pressure From Baseline
Baseline and Week 24 (plus/minus 5 days) · millimetre of mercury (mmHg)
| Riociguat >=6 to <18 Years | -3.1 ± 10.5 millimetre of mercury (mmHg) |
|---|
| Riociguat >=6 to <18 Years | -2.4 ± 10.0 millimetre of mercury (mmHg) |
|---|
Open in BENITIONS
View on ClinicalTrials.gov
All trials
This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.